Reviewer ’s report  
 
Title: Telbivudine treatment started in early and middle pregnancy completely blocks HBV 
vertical transmission  
 
Version: 1 Date: 05 Jan 2017  
 
Reviewer: Hyun Woong Lee  
 
Reviewer's report:  
 
Dear Sun Weihui  
 
"Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical 
transmission"  
Thank you for the authors' effort to revise the manuscript accodrin g to our review. In my 
opinion, this manuscript was well modified for publication.  
 
However, there are minor problems that should be address  
1. Please check " HBV DNA≥ 1.0 DN7 copies/mL" in ABSTRACT.  
2. Please change "HVL" to "high viral load" in DISCUSSIO N 
3. Please check the sentence "Therefore, it is worth considering that whether risk the risk of 
resistance to prolong telbivudine treatment after delivery" in DISCUSSION.  
4. In Table 2, please change "HBV DNA viral load" to "HBV DNA viral loads, log10 
copies/ml".  
5. In Table 2, please change "ALT levels" to "ALT levels, IU/mL".  
Are the methods appropriat e and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
Does the work include the necessary controls?  
 
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions dra wn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manuscript or would you recommend an  
additional statistical review?  
If an additional statistical review is r ecommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an  
organisation that may in any way gain or lose financially from the publication of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financially from the publication of this  manuscript, either now or in the future?  
 
3. Do you hold or are you currently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds  or has applied f or patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
I declare that I have no competing interests  
 
I agree to the open peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, if the manuscript is accepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments  
which I do not wish to be included in my named report can be included as confidential comments  
to the editors, which will not be published.  
 
I agree to the open pee r review policy of the journal  
Reviewer ’s report  
 
Title: Telbivudine treatment started in early and middle pregnancy completely blocks HBV 
vertical transmission  
 
Version: 1 Date: 05 Jan 2017  
 
Reviewer: Hyun Woong Lee  
 
Reviewer's report:  
 
Dear Sun Weihui  
 
"Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical 
transmission"  
Thank you for the authors' effort to revise the manuscript accodrin g to our review. In my 
opinion, this manuscript was well modified for publication.  
 
However, there are minor problems that should be address  
1. Please check " HBV DNA≥ 1.0 DN7 copies/mL" in ABSTRACT.  
2. Please change "HVL" to "high viral load" in DISCUSSIO N 
3. Please check the sentence "Therefore, it is worth considering that whether risk the risk of 
resistance to prolong telbivudine treatment after delivery" in DISCUSSION.  
4. In Table 2, please change "HBV DNA viral load" to "HBV DNA viral loads, log10 
copies/ml".  
5. In Table 2, please change "ALT levels" to "ALT levels, IU/mL".  
Are the methods appropriat e and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
Does the work include the necessary controls?  
 
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions dra wn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manuscript or would you recommend an  
additional statistical review?  
If an additional statistical review is r ecommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an  
organisation that may in any way gain or lose financially from the publication of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financially from the publication of this  manuscript, either now or in the future?  
 
3. Do you hold or are you currently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds  or has applied f or patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
I declare that I have no competing interests  
 
I agree to the open peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, if the manuscript is accepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments  
which I do not wish to be included in my named report can be included as confidential comments  
to the editors, which will not be published.  
 
I agree to the open pee r review policy of the journal  
Please review this paper.
user
Reviewer ’s report  
 
Title: Telbivudine treatment started in early and middle pregnancy completely blocks HBV 
vertical transmission  
 
Version: 1 Date: 05 Jan 2017  
 
Reviewer: Hyun Woong Lee  
 
Reviewer's report:  
 
Dear Sun Weihui  
 
"Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical 
transmission"  
Thank you for the authors' effort to revise the manuscript accodrin g to our review. In my 
opinion, this manuscript was well modified for publication.  
 
However, there are minor problems that should be address  
1. Please check " HBV DNA≥ 1.0 DN7 copies/mL" in ABSTRACT.  
2. Please change "HVL" to "high viral load" in DISCUSSIO N 
3. Please check the sentence "Therefore, it is worth considering that whether risk the risk of 
resistance to prolong telbivudine treatment after delivery" in DISCUSSION.  
4. In Table 2, please change "HBV DNA viral load" to "HBV DNA viral loads, log10 
copies/ml".  
5. In Table 2, please change "ALT levels" to "ALT levels, IU/mL".  
Are the methods appropriat e and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
Does the work include the necessary controls?  
 
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions dra wn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manuscript or would you recommend an  
additional statistical review?  
If an additional statistical review is r ecommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an  
organisation that may in any way gain or lose financially from the publication of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financially from the publication of this  manuscript, either now or in the future?  
 
3. Do you hold or are you currently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds  or has applied f or patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
I declare that I have no competing interests  
 
I agree to the open peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, if the manuscript is accepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments  
which I do not wish to be included in my named report can be included as confidential comments  
to the editors, which will not be published.  
 
I agree to the open pee r review policy of the journal  
assistant